ReleaseWire Connect

CordLife India has now using a novel process cord blood using the upgraded Swiss-made technology Sepax 2 and the extension of their stem cell storage tenure to 25 years. The company is the first stem cell bank in India to have implemented these advancements.

Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), a leading cord blood and tissue banking service provider, announced today that its Indian subsidiary, Cordlife Sciences India Pvt. Ltd (“Cordlife India”), has attained accreditation from AABB, an international, not-for-profit association representing individuals and institutions involved in the field of transfusion medicine and cellular therapies. It has been granted the International Certificate of Accreditation for activities relating to the processing, storage and distribution of cord blood.

CordLife India, the largest and most advanced cord blood bank facility in the country, has come up with the Umbilical Cord banking service for the clients. It is considered to be a reliable company that offers different technology of differentiating, isolating, and expanding the two cell lines from the umbilical cord.

Cordlife Limited is the only Stem cell Bank in India that has the technology to extract Epithelial (EpSCs) and Mesenchymal (MSCs) stem cells with immense potential in aiding the repair of injured tissues and organs and aids in treatment of various other diseases. Nonetheless, Cordlife Limited is the only bank that offers stem cell therapy in India with EpSCs extraction.

Cordlife Limited with its proven expertise and quality gives new dimensions and new definitions to cord blood banking in India. They have got the largest network of private cord blood banks in Asia Pacific and provide state-of-the-art cord blood, tissue processing and cryopreservation facilities in India, Indonesia and the Philippines.

CordLife India, the largest and most advanced cord blood bank facility in the country, introduced Umbilical Cord banking to the clients. It is the only company in India that offers novel and patented technology of isolating, differentiating and expanding the two cell lines from the umbilical cord. Their state-of-the-art laboratory is equipped with full processing, testing and cryopreservation capability that guaranties the safe and secure reservation of the umbilical cords.

Cordlife Quality Guarantee gives their client a complete peace of mind as they assure of a cord blood replacement at no cost or a compensation of up to US$30,000, in case the cord blood loses its viability at the point of transplant. Nonetheless, banking of umbilical cord with Cordlife is once in a life time chance to collect cord blood which should not be wasted.

Cord blood banking in India, also called “placental blood,” is blood that remains in the umbilical cord and placenta following the birth of a baby. It is a unique and one of its own kind of facility provided in India. During pregnancy, the umbilical cord functions as a lifeline between mother and child. After a baby’s delivery, the cord blood present in the umbilical cord could offer future hope for the child or other members of the family.

CordLife India, a leading healthcare company that provides a full suite of cord blood and tissue banking, offers quality guarantee on its cord blood banking facilities. Cord Life's reliability and confidence is embodied in its quality guarantee protecting all clients. Cord Life India is the only healthcare center in India that provides quality guarantee on cord blood banking. The quality guarantee gives peace of mind as it assures of cord blood replacement at no cost or a compensation of up to US $30,000 if the cord blood loses its viability at the point of transplant. The company's in-depth knowledge in stem cell banking practices and standards is well-recognized by numerous world-class quality standard organizations as well as country regulators on the Asia Pacific region. Cord blood banking has gained popularity in India in the recent years. CordLife India targets to secure every baby's future. The company's in-depth knowledge of umbilical cord banking practices and standards is well-known in numerous world-class quality standard organizations as well as country regulators in Asia-Pacific region. In 2007 Cord Life India was bestowed with the prestigious “Technology Pioneer” title by the World Economic Forum which further validated the Company's outstanding performance in the industry. Only Cord Life has the technology to extract EpSCs from the baby's umbilical cord. Listed on Australian Securities Exchange, CordLife Limited is well-established as the largest network of private stem cell banks across Asia-Pacific. Its state-of-the-art cord blood and tissue-processing and cryopreservation facilities are available in India, Indonesia and the Philippines as well as a network that extends to Singapore, Hong Kong and China. About the company: CordLife India is a majority-owned subsidiary of CordLife Limited, a company listed on the Australian Securities Exchange. A winner of Technology Pioneer award conferred by the World Economic Forum, CordLife has accumulated more than 10 years of experience in stem cell processing and cryopreservation. CordLife Limited owns and operates 3 state-of-the-art stem cell processing and cryopreservation facilities in India, Indonesia and the Philippines along with a network extending to other full-fledged facilities in Singapore, Hong Kong and Mainland China.

Cord blood and tissue banking service provider Cordlife Group posted a net profit of S$5.6 million for its fiscal second quarter, boosted by a one-time disposal gain of $2.7 million.